In last trading session, Corcept Therapeutics Inc (NASDAQ:CORT) saw 2.62 million shares changing hands with its beta currently measuring 0.33. Company’s recent per share price level of $71.79 trading at $2.52 or 3.64% at ring of the bell on the day assigns it a market valuation of $7.57B. That closing price of CORT’s stock is at a discount of -63.44% from its 52-week high price of $117.33 and is indicating a premium of 69.36% from its 52-week low price of $22.00. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.49 million shares which gives us an average trading volume of 1.55 million if we extend that period to 3-months.
For Corcept Therapeutics Inc (CORT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0.14 in the current quarter.
Corcept Therapeutics Inc (NASDAQ:CORT) trade information
Upright in the green during last session for gaining 3.64%, in the last five days CORT remained trading in the green while hitting it’s week-highest on Thursday, 04/24/25 when the stock touched $71.79 price level, adding 5.75% to its value on the day. Corcept Therapeutics Inc’s shares saw a change of 42.47% in year-to-date performance and have moved 11.13% in past 5-day. Corcept Therapeutics Inc (NASDAQ:CORT) showed a performance of 23.10% in past 30-days. Number of shares sold short was 16.53 million shares which calculate 9.7 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 77 to the stock, which implies a rise of 6.77% to its current value. Analysts have been projecting 38 as a low price target for the stock while placing it at a high target of 80. It follows that stock’s current price would jump 47.07% in reaching the projected high whereas dropping to the targeted low would mean a gain of 47.07% for stock’s current value.
Corcept Therapeutics Inc (CORT) estimates and forecasts
This year revenue growth is estimated to rise 34.12% from the last financial year’s standing.
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 177.93M for the same. And 4 analysts are in estimates of company making revenue of 216.68M in the next quarter. Company posted 146.81M and 163.8M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 9.89% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 37.80% while estimates for its earnings growth in next 5 years are of 70.53%.
Corcept Therapeutics Inc (NASDAQ:CORT)’s Major holders
Insiders are in possession of 11.44% of company’s total shares while institution are holding 80.75 percent of that, with stock having share float percentage of 91.18%. Investors also watch the number of corporate investors in a company very closely, which is 80.75% institutions for Corcept Therapeutics Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at CORT for having 16.54 million shares of worth $537.36 million. And as of 2024-06-30, it was holding 16.0391 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 9.55 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.2648 of outstanding shares, having a total worth of $310.4 million.
On the other hand, iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 5.77 shares of worth $413.96 million or 5.47% of the total outstanding shares. The later fund manager was in possession of 2.8 shares on Dec 31, 2024 , making its stake of worth around $201.34 million in the company or a holder of 2.66% of company’s stock.
